目的 观察瑞马唑仑复合丙泊酚用于超声引导下取卵术中的麻醉效果。 方法 选取2024年7月至2025年1月行择期体超声引导下取卵术的患者145例，按随机数字表法分为3组：丙泊酚组（P组）、0.05 mg/kg瑞马唑仑复合合丙泊酚组（PR₁组）、0.1 mg/kg瑞马唑仑复合丙泊酚组（PR₂组）。3组均先静脉注射舒芬太尼0.1 μg/kg，PR₁组静脉注射瑞马唑仑0.05 mg/kg和丙泊酚1 ~ 3 mg/kg，PR₂组静脉注射瑞马唑仑0.1 mg/kg和丙泊酚1 ~ 3 mg/kg；P组静脉注射等剂量的生理盐水和丙泊酚1 ~ 3 mg/kg。记录3组患者在麻醉诱导前（T₀）、诱导成功后（T₁）、穿刺时（T₂）、取卵开始后5 min（T₃）、苏醒时（T₄）、苏醒后10 min（T₅）的生命体征。记录丙泊酚用量，镇静成功率、记录术后1 min MOAA/S评分及PADSS评分≥ 9分所需时间。记录不良反应（呼吸抑制、低血压、心动过缓、恶心呕吐、呃逆）的发生情况。 结果 与P组相比，PR₁组与PR₂组在T₁时心率、血压均较高（均P < 0.05）。与P组和PR₁组相比，PR₂组在T₂时心率、血压较低（均P < 0.05）。与P组相比，PR₁组和PR₂组在T₃时心率、血压均较低（均P < 0.05），3组各时点的SpO₂差异无统计学意义（P > 0.05）。与P组相比，PR₁组和PR₂组丙泊酚用量减少（均P＜0.05），镇静成功率高（均P < 0.05），术后1 min MOAA/S评分较高（均P < 0.05），PADSS评分≥ 9分所需时间短（均P < 0.05）。与PR₁组相比，PR₂组丙泊酚用量更少（P < 0.05），镇静成功率更高（P < 0.05）。与P组相比，PR₁与PR₂组呼吸抑制与低血压的发生率均较低（均P < 0.05）。3组患者恶心呕吐、呃逆的发生率差异无统计学意义（P > 0.05）。 结论 0.1 mg/mL的瑞马唑仑复合丙泊酚在取卵手术中的麻醉效果优于单独使用丙泊酚，值得临床推广应用。

Objective To observe the anesthetic effect of remimazolam combined with propofol in ultrasound-guided oocyte retrieval surgery. Methods A total of 145 patients who underwent elective transvaginal ultrasound-guided oocyte retrieval from July 2024 to January 2025 were selected. They were randomly divided into three groups according to the random number table method： the propofol group （Group P）， the 0.05 mg/kg remimazolam combined with 0.1 mg/kg （Group PR₁）， and the 0.1 mg/kg remimazolam combined with propofol group （Group PR₂）. All groups were intravenously infused with sufentanil at 0.1 μg/kg at first. Group PR₁ was intravenously infused with remimazolam at 0.05 mg/kg and propofol at 1 to 3 mg/kg； Group PR₂ was intravenously infused with remimazolam at 0.1 mg/kg and propofol at 1 to 3 mg/kg； Group P was intravenously infused with an equal volume of 0.9% saline and propofol at 1 to 3 mg/kg. The vital signs of the patients in the three groups were recorded at before anesthesia induction （T₀）， after successful induction （T₁）， during puncture （T₂）， 5 minutes after the start of the operation （T₃）， at the time of awakening （T₄）， and 10 minutes after awakening （T₅）. The dosage of propofol， the success rate of sedation， the MOAA/S score at 1 minute after surgery， and the time required for the PADSS score to reach ≥ 9 were recorded. The occurrence of adverse reactions （respiratory depression， hypotension， bradycardia， nausea and vomiting， hiccups） was also recorded. Results Compared with group P， group PR1 and group PR₂ had higher heart rate and blood pressure at T1 （both P < 0.05）. Compared with group P and group PR₁， group PR₂ had lower heart rate and blood pressure at T₂ （both P < 0.05）. Compared with group P， both group PR1 and group PR₂ had lower heart rate and blood pressure at T₃ （both P < 0.05）， with no statistically significant difference in SPO₂ at each time point among the three groups （P > 0.05）. Compared with group P， the propofol dosage in groups PR₁ and PR₂ was reduced （both P < 0.05）， with a higher sedative success rate （both P < 0.05）， and higher MOAA/S scores at 1 minute post-operation （both P < 0.05）； the time required for PADSS scores to reach ≥ 9 was shorter （both P < 0.05）. Compared with group PR₁， group PR₂ used even less propofol （P < 0.05） and had a higher sedative success rate （P < 0.05）. Compared with group P， the incidence of respiratory depression and hypotension was lower in both groups PR₁ and PR₂ （both P < 0.05）. There was no statistically significant difference in the incidence of nausea， vomiting， and hiccups among the three groups （P > 0.05）. Conclusion 0.1 mg/mL of remimazolam combined with propofol has a good anesthetic effect in oocyte retrieval procedures and is worthy of clinical promotion and application.